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Introduction {#sec005}
============

Polycystic ovarian syndrome (PCOS) is the most common endocrine abnormality, affecting 6--14% of reproductive-aged women \[[@pone.0157389.ref001]\]. However, PCOS is not a gynecological disorder alone, and obesity, insulin resistance (IR), and metabolic syndrome frequently appear in women with PCOS, which leads to increased incidence of longer-term health consequences, such as type 2 diabetes mellitus and cardiovascular events \[[@pone.0157389.ref002]\]. Therefore, the importance of managing PCOS in order to prevent the development of cardiovascular disease (CVD) has been recognized \[[@pone.0157389.ref003]\].

CVD has various risk factors, such as elevated blood pressure, cholesterol, or glucose levels and smoking. Homocysteine, a sulfur-containing amino acid, is associated with an increased risk of atherosclerotic and thromboembolic disorders as well as hyperinsulinemia \[[@pone.0157389.ref004]\]. Researchers have considered elevated homocysteine levels a "classical" risk factor for CVD \[[@pone.0157389.ref005]\]. Hyperhomocysteinemia may arise from nutritional deficiencies of folate, vitamin B~6~, and vitamin B~12~ \[[@pone.0157389.ref006]\]. Indeed, IR and obesity have been associated with lower serum vitamin B~12~ concentrations in PCOS patients \[[@pone.0157389.ref007]\]. Elevated serum total testosterone level, another biochemical characteristic of PCOS, is also a main factor associated with hyperhomocysteinemia in PCOS patients \[[@pone.0157389.ref008]\]. Previous meta-analyses have demonstrated higher homocysteine levels in PCOS patients than in healthy controls \[[@pone.0157389.ref009], [@pone.0157389.ref010]\]. Therefore, high circulating homocysteine levels may be an intrinsic characteristic of PCOS, and lowering homocysteine levels offers new possibilities for preventing CVD in women with PCOS.

Over the past decade, many studies have investigated homocysteine levels in women with PCOS; in addition, the relationships between homocysteine and PCOS' biochemical characteristics---such as obesity, IR, and elevated androgen levels---have also been researched \[[@pone.0157389.ref007], [@pone.0157389.ref011]--[@pone.0157389.ref043]\]. However, these studies have shown inconsistent results, and the mechanism for high homocysteine levels in women with PCOS is still not fully understood. Although two previous meta-analyses have shown high homocysteine levels in PCOS patients, they did not illustrate the relationship between elevated homocysteine levels and biochemical characteristics of women with PCOS, which would limit the application of managing homocysteine levels in the treatment of PCOS. The purpose of this systematic review and meta-analysis is to investigate the relationship between characteristics of PCOS and homocysteine levels. In addition, metformin is widely used in PCOS patients for IR treatment. Vitamin B12 level is known to decrease during metformin treatment \[[@pone.0157389.ref044]\], and vitamin B12 is strongly associated with serum homocysteine \[[@pone.0157389.ref045]\]. Hence, homocysteine level might increase during metformin treatment. We therefore further investigate the effect of metformin treatment on homocysteine levels in PCOS patients.

Materials and Methods {#sec006}
=====================

The present meta-analysis was performed according to the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) \[[@pone.0157389.ref046]\] ([S1 Table](#pone.0157389.s005){ref-type="supplementary-material"}). There was no registered protocol.

Identification of studies and eligibility criteria {#sec007}
--------------------------------------------------

Two investigators (YM and XC) independently conducted a systematic literature search in PubMed, Embase, and the Cochrane Library database for relevant studies from inception through December 2015. In addition, we searched the reference lists of all identified relevant publications, review and meta-analysis articles. Only English language and human studies were searched. Disagreement was resolved by group consultation.

The literature search using exploded Medical Subject Headings (MeSH) terms and corresponding keywords. The search terms used were: (MeSH exp 'Polycystic Ovary Syndrome' and keywords 'PCOS'), and (MeSH exp 'Homocysteine' and keywords 'Hcy').

For the study selection, the first eligibility criteria was PCOS clearly defined according to the Rotterdam criteria \[[@pone.0157389.ref047]\] or National Institute of Health (NIH) criteria \[[@pone.0157389.ref048]\] or Androgen Excess & PCOS Society 2006 criteria\[[@pone.0157389.ref049]\]. The second criteria was that body mass index (BMI) and age should be matched between PCOS patients and controls. All included studies perfectly meet the above two criteria and also include serum homocysteine means and standard deviations (SDs) for cases and controls. To best understand the association between homocysteine and IR in PCOS, studies of homocysteine levels in PCOS patients treated with metformin were also included in this meta-analysis.

Studies without a control group or subjects with diseases other than PCOS were excluded. Letters, case reports, editorials, and conference abstracts were also excluded.

Quality score assessment {#sec008}
------------------------

The quality of the included studies in this meta-analysis was assessed according to the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@pone.0157389.ref050]\], and the assessment items were established according to the study by Murri et al. \[[@pone.0157389.ref010]\]. Studies with an NOS score ≤5 were considered "medium" quality studies. "High" quality studies were defined as having a quality score \>5. The maximum NOS score was 8.

Data extraction {#sec009}
---------------

Two investigators (YM and XC) independently extracted the following data from the retrieved studies: name of the first author, publication date, country, sample size, diagnostic criteria for PCOS, matched factors, mean BMI and age, mean serum homocysteine level and standard deviation (SD), measurement method, IR status, and androgen status. The two researchers attempted to obtain the necessary data by contacting the authors of the original articles as needed (i.e., when the homocysteine levels were reported as median or geometric values). The data were extracted by the two investigators were expected to be the same, and any dispute was resolved by group consultation.

Statistical analysis {#sec010}
--------------------

Homocysteine levels were extracted as the mean ± SD from the included studies. The assessment of IR was based on the ratio of the mean Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) values in the PCOS group to that of the controls (HOMA-IR ratio). Similarly, androgen status was assessed according to the ratio of the mean testosterone level (total or free) in PCOS to that of the controls (T ratio). Because various measurement methods and units for homocysteine level were used across studies, we used standardized mean difference (SMD) but not weighted mean difference (WMD), with the corresponding 95% confidence intervals (95% CIs) as a measure of effect size in this meta-analysis.

Heterogeneity was assessed using a chi-squared Q test and I-squared statistics. If *P*~*Q*~\<0.1 or *I*^*2*^\>50%, the heterogeneity was considered significant, and a random-effects model (the DerSimonian and Laird method) was used. Otherwise, a fixed-effects model was used. To better understand the relationship between homocysteine level and the basic characteristics of PCOS, such as BMI, IR status, and androgen status, the corresponding subgroup analysis was carried out according to predefined criteria. BMI values were used to categorize patients into a normal-weight group (BMI \<25 kg/m^2^) or an over-weight group (BMI ≥25 kg/m^2^). Quartile intervals were used to categorize patients according to HOMA2-IR ratio and T ratio.

If statistically significant heterogeneity was observed in this meta-analysis, a univariate meta-regression analysis for the potential variables between studies was first performed. In the meta-regression model, the SMD was used as the dependent variable, and potential confounder factors---such as the diagnosis criteria, BMI, NOS score, HOMA-IR ratio, and T ratio---were used as covariates. Covariates with values of *P*\>0.05 were not considered to be sources of heterogeneity. If the variables were significant at the 0.1 level, a multivariable analysis was further performed.

Sensitivity analysis was used to examine the influence of individual studies by excluding the studies one by one \[[@pone.0157389.ref051]\]. Publication bias was estimated by Begg's test and further confirmed by Egger's regression \[[@pone.0157389.ref051]\].

RevMan 5.2.7 (Cochrane Collaboration) and STATA software (version 12.0; Stata Corporation, College Station, TX) were used in this meta-analysis.

Results {#sec011}
=======

Literature selection {#sec012}
--------------------

This meta-analysis finally included 41 eligible studies, of which 34 \[[@pone.0157389.ref007], [@pone.0157389.ref011]--[@pone.0157389.ref043]\] were in quantitative synthesis for homocysteine levels in PCOS, and seven \[[@pone.0157389.ref021], [@pone.0157389.ref022], [@pone.0157389.ref052]--[@pone.0157389.ref056]\] covered homocysteine levels in PCOS patients treated with metformin. [Fig 1](#pone.0157389.g001){ref-type="fig"} shows the search flow diagram; in addition, the excluded articles with reasons for exclusion were shown in [S1 File](#pone.0157389.s004){ref-type="supplementary-material"}.

![Flow diagram of included studies for this meta-analysis.](pone.0157389.g001){#pone.0157389.g001}

Characteristics of the included studies {#sec013}
---------------------------------------

For the serum homocysteine level in women with PCOS, the characteristics of the included studies are shown in [Table 1](#pone.0157389.t001){ref-type="table"}. All the included studies were age and BMI matched between PCOS and control groups except the study by Yarali et al. \[[@pone.0157389.ref018]\]. In addition, five studies further matched PCOS and control groups in terms of B~12~ and folate levels \[[@pone.0157389.ref007], [@pone.0157389.ref014], [@pone.0157389.ref022], [@pone.0157389.ref025], [@pone.0157389.ref035]\]. The selection of PCOS patients in seven studies \[[@pone.0157389.ref015], [@pone.0157389.ref016], [@pone.0157389.ref018], [@pone.0157389.ref026], [@pone.0157389.ref035], [@pone.0157389.ref036], [@pone.0157389.ref042]\] was according to NIH, and the other 27 studies \[[@pone.0157389.ref007], [@pone.0157389.ref011]--[@pone.0157389.ref014], [@pone.0157389.ref017], [@pone.0157389.ref019]--[@pone.0157389.ref025], [@pone.0157389.ref027]--[@pone.0157389.ref034], [@pone.0157389.ref037]--[@pone.0157389.ref041], [@pone.0157389.ref043]\] used the Rotterdam criteria. Three studies were assessed as "medium" quality \[[@pone.0157389.ref018], [@pone.0157389.ref035], [@pone.0157389.ref043]\] and the other 31 were all "high" quality studies according to NOS. For studies covering homocysteine levels in PCOS patients treated with metformin, the metformin dose and duration of treatment are shown in [Table 2](#pone.0157389.t002){ref-type="table"}, as well as the other basic characteristics of PCOS patients, such as the definition of PCOS, BMI, sample size, and homocysteine levels before and after treatment.

10.1371/journal.pone.0157389.t001

###### Characteristics of included studies in meta-analysis.

![](pone.0157389.t001){#pone.0157389.t001g}

  Study             Year   Country          Detecting method          Diagnosis criteria   Matched factors          BMI    No. ~PCOS/Control~   HOMA ratio   T ratio   NOS score
  ----------------- ------ ---------------- ------------------------- -------------------- ------------------------ ------ -------------------- ------------ --------- -----------
  Yarali            2001   Turkey           FPIA                      NIH                  BMI,B12,Folate           ≥25    30/30                NR           1.42      5
  Orio              2003   Italy            HPLC                      NIH                  Age,BMI,B12,Folate       \<25   70/70                3.30         1.65      6
  Kilic-Okman       2004   Turkey           Chemiluminescence         NIH                  Age, BMI                 ≥25    29/25                1.82         NR        7
  Bayraktar         2004   Turkey           HPLC                      NIH                  Age,BMI,B12,Folate       \<25   50/25                1.62         1.80      4
  Bickerton         2005   United Kingdom   ETMS                      NIH                  Age, BMI                 ≥25    11/12                NR           1.56      6
  Yilmaz            2005   Turkey           HPLC                      ESHRE/ASRM           Age,BMI,B12,Folate       \<25   50/35                1.46         1.46      6
  Topcu             2006   Turkey           NR                        ESHRE/ASRM           Age, BMI                 ≥25    28/26                1.67         1.83      6
  Sahin             2007   Turkey           FPIA                      ESHRE/ASRM           Age, BMI                 \<25   20/20                NR           3.16      7
  Guzelmeric        2007   Turkey           FPIA                      NIH                  Age, BMI                 ≥25    44/26                1.61         1.88      7
  Atamer            2008   Turkey           Fluorescence detection    ESHRE/ASRM           Age, BMI                 ≥25    35/30                1.72         2.31      6
  Heutling          2008   Germany          HPLC                      ESHRE/ASRM           Age, BMI                 ≥25    83/39                1.72         1.67      8
  Battaglia         2008   Italy            FPIA                      NIH                  Age, BMI                 ≥25    28/15                2.07         2.13      7
  Kaya              2009   Turkey           HPLC                      ESHRE/ASRM           Age,BMI,B12,Folate       ≥25    61/61                2.06         1.75      8
  Oktem             2009   Turkey           FPIA                      ESHRE/ASRM           Age, BMI                 ≥25    31/31                1.63         1.40      5
  Cetinkalp         2009   Turkey           NR                        ESHRE/ASRM           Age, BMI                 \<25   129/91               2.68         0.93      7
  Soares            2009   Brazil           Chemiluminescence         ESHRE/ASRM           Age, BMI                 \<25   40/50                1.04         1.54      7
  Kaya              2010   Turkey           HPLC                      ESHRE/ASRM           Age, BMI                 \<25   68/68                2.85         2.34      8
  Nafiye            2010   Turkey           Chemiluminescence         ESHRE/ASRM           Age, BMI                 ≥25    36/61                1.92         NR        8
  Karaer            2010   Turkey           Competitive immunoassay   ESHRE/ASRM           Age,BMI,B12,Folate       ≥25    31/31                1.86         1.38      8
  Fulghesu          2010   Italy            Chemiluminescence         ESHRE/ASRM           Age, BMI                 \<25   71/94                1.06         2.00      7
  Karadeniz         2010   Turkey           FPIA                      ESHRE/ASRM           Age, BMI                 \<25   86/70                2.64         34.33     6
  Arikan            2010   Turkey           Chemiluminescence         ESHRE/ASRM           Age, BMI                 \<25   31/25                1.73         3.00      6
  Mohamadin         2010   Saudi Arabia     ELISA                     ESHRE/ASRM           Age, BMI                 ≥25    50/40                1.89         2.32      6
  Temel             2010   Turkey           ELISA                     ESHRE/ASRM           Age, BMI                 \<25   30/30                1.82         1.37      6
  Salehpour         2011   Iran             RIA                       ESHRE/ASRM           Age, BMI                 ≥25    85/83                NR           NR        6
  Altug             2011   Turkey           FPIA                      ESHRE/ASRM           Age,BMI,B12,Folate       \<25   24/20                1.76         1.74      6
  Hemati            2011   Iran             ELISA                     ESHRE/ASRM           Age, physical activity   \<25   64/50                2.52         2.21      7
  Caglar            2011   Turkey           NR                        ESHRE/ASRM           Age, BMI                 \<25   61/21                1.75         1.56      8
  Bayrak            2012   Turkey           FPIA                      ESHRE/ASRM           Age,BMI,smoking          \<25   77/25                1.58         1.83      7
  Deveer            2012   Turkey           Chemiluminescence         ESHRE/ASRM           Age, BMI                 \<25   25/25                1.74         1.28      8
  Harmanci          2013   Turkey           HPLC                      ESHRE/ASRM           Age, BMI                 \<25   23/23                1.28         1.96      7
  Maleedhu          2014   India            EIA                       ESHRE/ASRM           Age, BMI                 \<25   142/65               NR           NR        6
  Moti              2015   Iran             HPLC                      ESHRE/ASRM           Age, BMI                 \<25   30/30                1.82         NR        7
  Miranda-Furtado   2015   Brazil           NR                        ESHRE/ASRM           Age, BMI                 ≥25    45/52                1.80         1.21      7

FPIA, fluorescence polarization immunoassay; EIA, Enzyme Immunoassay; ETMS, electrospray tandem mass spectrometry; NIH, National Institute of Health criteria; ESHRE/ASRM, Rotterdam criteria; BMI, body mass index; NR, no reporting; NOS, Newcastle-Ottawa Quality Assessment Scale

10.1371/journal.pone.0157389.t002

###### Characteristics of included studies for Hcy levels in metformin treated with PCOS.

![](pone.0157389.t002){#pone.0157389.t002g}

  Study            Year   Country          Definition of PCOS   Dose of treatment                                                       Time of treatment   BMI    N~PCOS~   Before treatment   After treatment           
  ---------------- ------ ---------------- -------------------- ----------------------------------------------------------------------- ------------------- ------ --------- ------------------ ----------------- ------- ------
  Vrbikova         2002   Czech Republic   NIH                  first week:500mg q.d., then 1000mg q.d.                                 7 months            ≥25    9         10.1               2.6               13.4    5.1
  Kilicdag         2005   Turkey           ESHRE/ASRM           850mg b.i.d.                                                            3 months            ≥25    14        9.56               0.81              11.97   1.01
  Yilmaz           2005   Turkey           ESHRE/ASRM           850 mg b.i.d.                                                           3 months            \<25   25        13.52              5.98              13.46   6.01
  Sahin            2007   Norway           ESHRE/ASRM           2550 mg q.d.                                                            6 months            \<25   20        12.8               5.2               12.3    5.6
  Schachter        2007   Israel           ESHRE/ASRM           1700mg q.d.                                                             3 months            ≥25    28        10.5               0.9               8.6     0.7
  Haydardedeoglu   2009   Turkey           ESHRE/ASRM           850 mg b.i.d.                                                           3 months            ≥25    20        8.74               1.9               10.97   3.31
  Rajagopal        2012   India            NIH                  first week: 500mg q.d. next week: 500mg b.i.d. then to 1,000mg b.i.d.   3 months            ≥25    25        20                 7.3               18.2    8.9

NIH, National Institute of Health criteria; ESHRE/ASRM, Rotterdam criteria; BMI, body mass index; SD, standard deviations

Meta-analysis of homocysteine levels in women with PCOS {#sec014}
-------------------------------------------------------

When the 34 included studies with 1,718 cases and 1,399 controls were pooled in meta-analysis, significantly lower homocysteine levels were found in controls than in PCOS patients (SMD = 0.895, 95% CI = 0.643--1.146, and *P*\<0.001). However, significant heterogeneity was observed across studies (*I*^*2*^ = 90.4% and *P*\<0.001, [Fig 2](#pone.0157389.g002){ref-type="fig"} and [Table 3](#pone.0157389.t003){ref-type="table"}).

![Forest plot of the pooled quantitative synthesis and subgroup analysis stratified by HOMA-IR ratio.](pone.0157389.g002){#pone.0157389.g002}

10.1371/journal.pone.0157389.t003

###### Subgroup analysis results in meta-analysis.

![](pone.0157389.t003){#pone.0157389.t003g}

  Subgroup                 No. study   No. PCOS   No. Control   SMD (95%CI)           *P*~value~   Heterogeneity   
  ------------------------ ----------- ---------- ------------- --------------------- ------------ --------------- ---------
  **Overall**              34          1718       1399          0.895(0.643--1.146)   \<0.001      90.4            \<0.001
  **Diagnosis criteria**                                                                                           
  NIH                      7           262        203           1.109(0.324--1.895)   0.006        92.9            \<0.001
  ESHRE/ASRM               27          1456       1196          0.845(0.579--1.111)   \<0.001      90.0            \<0.001
  **BMI**                                                                                                          
  Over-weight              14          597        532           0.817(0.547--1.088)   \<0.001      77.6            \<0.001
  Normal-weight            20          1121       867           0.940(0.557--1.323)   \<0.001      93.3            \<0.001
  **HOMA-IR ratio**                                                                                                
  ≤1.62                    7           355        278           1.271(0.241--2.301)   0.016        96.6            \<0.001
  1.63--1.75               7           294        197           0.582(0.099--1.065)   0.018        84.0            \<0.001
  1.76--1.92               7           239        228           1.110(0.538--1.681)   \<0.001      87.7            \<0.001
  \>1.92                   8           542        486           0.776(0.424--1.128)   \<0.001      85.9            \<0.001
  No data                  5           288        210           0.738(0.439--1.037)   \<0.001      51.7            0.082
  **T-ratio**                                                                                                      
  \<1.54                   8           371        325           0.598(0.260--0.937)   0.001        77.5            \<0.001
  1.54--1.79               7           350        273           0.479(0.052--0.906)   0.028        83.5            \<0.001
  1.80--2.20               7           321        234           1.567(0.519--2.614)   0.003        95.9            \<0.001
  \>2.20                   7           354        303           0.836(0.474--1.197)   \<0.001      78.6            \<0.001
  NR                       5           322        264           1.095(0.607--1.583)   \<0.001      85.1            \<0.001
  **NOS score**                                                                                                    
  Medium                   3           188        146           1.040(0.664--1.416)   \<0.001      51.0            0.130
  High                     31          1530       1253          0.881(0.605--1.156)   \<0.001      91.0            \<0.001

NIH, National Institute of Health criteria; ESHRE/ASRM, Rotterdam criteria; BMI, body mass index; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; T, testosterone; NOS, Newcastle-Ottawa Quality Assessment Scale

To investigate the association between characteristics of PCOS patients and homocysteine level, subgroup analyses were performed. Studies with data not reported or not available were categorized into a non-reporting (NR) group. Quartile intervals for HOMA2-IR ratios were ≤1.62, 1.63--1.75, 1.76--1.92, and \>1.92. Quartile intervals for T ratios were \<1.54, 1.54--1.79, 1.80--2.20, and \>2.20. As shown in [Table 3](#pone.0157389.t003){ref-type="table"}, homocysteine levels in controls were significantly lower than those of PCOS patients in all predefined categories for HOMA2-IR ratio ([Fig 2](#pone.0157389.g002){ref-type="fig"}) and T ratio ([S1 Fig](#pone.0157389.s001){ref-type="supplementary-material"}). Similar results were found in the subgroup analyses according to diagnosis of PCOS, BMI ([S2 Fig](#pone.0157389.s002){ref-type="supplementary-material"}), and NOS score. However, significant heterogeneity was still found in all subgroup analyses. Meta-regression analyses were carried out to further investigate the source of heterogeneity. However, none of the potential variables between studies---such as quality score, BMI, diagnosis criteria, HOMA2-IR ratio, and T ratio---contributed to heterogeneity (*P*\>0.05, [Table 4](#pone.0157389.t004){ref-type="table"}).

10.1371/journal.pone.0157389.t004

###### Univariate meta-regression analysis for the potential variables between studies.

![](pone.0157389.t004){#pone.0157389.t004g}

  Covariates           No. study   Coefficient   SD      *t*     *P*     95%CI
  -------------------- ----------- ------------- ------- ------- ------- -------------------
  Quality Score        34          -0.172        0.517   -0.33   0.741   \[-1.227, 0.881\]
  BMI                  34          -0.098        0.3     -0.33   0.743   \[-0.709, 0.511\]
  HMOA-IR ratio        29          -0.38         0.335   -1.13   0.268   \[-1.068, 0.309\]
  T ratio              29          -0.004        0.027   -0.16   0.876   \[-0.060, 0.052\]
  Diagnosis Criteria   34          -0.252        0.368   -0.69   0.497   \[-1.002, 0.496\]

BMI, body mass index; HMOA-IR, Homeostasis Model Assessment of Insulin Resistance; T, total testosterone; SD, standard error

To investigate the influence of IR on homocysteine levels in women with PCOS, PCOS patients with IR were compared with non-IR patients. As shown in [Fig 3A](#pone.0157389.g003){ref-type="fig"}, the homocysteine levels in non-IR PCOS patients were significantly lower than those of PCOS patients with IR (SMD = 0.69, 95% CI = 0.37--1.01, *P*\<0.01; *I*^*2*^ = 0% and *P* = 0.50 for heterogeneity). However, metformin treatment did not appear to cause any significant change in the homocysteine levels of PCOS patients (SMD = --0.17, 95% CI = --1.10--0.75, *P* = 0.71; *I*^*2*^ = 92% and *P*\<0.01 for heterogeneity, [Fig 3B](#pone.0157389.g003){ref-type="fig"}).

![Forest plot of the influence of IR on homocysteine levels.\
A: PCOS patients with IR were compared with non-IR patients. B: Influence of metformin treatment on homocysteine levels.](pone.0157389.g003){#pone.0157389.g003}

Sensitivity analysis and publication bias {#sec015}
-----------------------------------------

The pooled SMDs and 95% CIs were not significantly changed when each study was omitted ([S3 Fig](#pone.0157389.s003){ref-type="supplementary-material"}). The study by Fulghesu et al. \[[@pone.0157389.ref031]\] is of particular interest; it showed an impressive positive result, but the pooled SMDs and 95% CIs were not significantly changed when it was excluded (SMD = 0.79, 95% CI = 0.59--0.99, and *P*\<0.001).

The results from Begg's test showed no significant publication bias in this meta-analysis, and Egger's regression results further confirmed this point (t = 1.01, *P* ~*Egger's*~ = 0.32, and 95% CI = --0.50--1.49).

Discussion {#sec016}
==========

In the present systematic review and meta-analysis, our results demonstrated significantly elevated homocysteine levels in PCOS patients when compared with controls, regardless of the degree of obesity, IR, or androgen levels, yet with significant between-study heterogeneity. Moreover, our results indicate that metformin treatment did not influence the homocysteine levels in PCOS patients.

For the overall analysis, our results are consistent with previous meta-analyses performed by Toulis et al. \[[@pone.0157389.ref009]\] and Murri et al.\[[@pone.0157389.ref010]\], although there are many differences between these studies (such as the number of included studies, exclusion criteria, and meta-analysis techniques). In addition, our study further investigated the relationship between elevated homocysteine levels and BMI, IR status, and androgen status. Interestingly, hyperhomocysteinemia was found both in normal-weight and over-weight women with PCOS, suggesting that increased homocysteine levels were not related to obesity. Previous case-control studies had found that elevated plasma homocysteine levels in PCOS patients were independent from obesity \[[@pone.0157389.ref057]\]. Indeed, even in the absence of obesity, patients with PCOS frequently have excessive body fat and central adiposity \[[@pone.0157389.ref058]\]. Combined with the results from the meta-regression model, our results suggest that obesity may be not a confounding factor that must be adjusted for in studies of homocysteine levels in women with PCOS.

Most of the included studies have shown higher IR and testosterone levels in women with PCOS than in controls (HOMA-IR ratio and T ratio\>1.0). Results from subgroup analysis indicate that homocysteine levels are elevated in PCOS patients regardless of the degree of IR and androgen levels. In addition, pooled results from three studies indicate that homocysteine levels were higher in PCOS patients with IR than in PCOS patients without IR. However, we did not find that homocysteine levels decreased after metformin treatment. These results suggest that IR may be one, but not the sole reason for the elevated homocysteine levels in women with PCOS. Indeed, an abnormal homocysteine status is not necessarily caused by a single factor; it is often the result of combined effects, such as age, gender, nutrition, and smoking status \[[@pone.0157389.ref059]\] as well as gene variants \[[@pone.0157389.ref060]\]. Hence, in one respect, our results suggest that metformin treatment may not decrease the risk of CVD by reducing homocysteine levels; however, combined with folate or vitamin B~12~ supplementation, it may be a beneficial additional treatment. In the meantime, our finding of no adverse effect of metformin on homocysteine homeostasis in PCOS women is reassuring. After all, metformin is the first-line drug in the treatment of PCOS.

Some limitations should be considered when examining the results of this meta-analysis. First, we found significant heterogeneity across eligible studies, which may reduce the reliability of our findings. We assessed heterogeneity using various statistical methods; however, the potential variables between studies---such as quality score, BMI, diagnosis criteria, HOMA2-IR ratio, and T ratio---were all not the main source of heterogeneity. Indeed, PCOS is a form of heterogeneous endocrinopathy with various clinical features, including hirsutism, acne, infertility, amenorrhea, and oligomenorrhea \[[@pone.0157389.ref002]\]. Moreover, most of the included studies in this meta-analysis have small sample sizes. In addition, the measurement for homocysteine levels in serum is not standardized, and various assays were used in previous studies. Considering these influences, it is understandable that significant heterogeneity was observed in our meta-analysis. Second, potential publication bias should be considered, despite the fact that Begg's test and Egger's regression showed no significant publication bias in this meta-analysis.

Despite these limitations, the strengths of our meta-analysis include a unique evaluation of the influence of the relationship between the main features of PCOS and homocysteine levels, especially in terms of obesity and IR status. Our results may shed some light on this unresolved issue. We also first evaluated the effect of metformin on homocysteine levels in PCOS patients. These are the main differences of this study compared with previously published systematic reviews and meta-analysis. In addition, the large number of subjects included in the analyses strengthen their statistical power, and we also strictly assessed literature quality according to NOS criteria. Finally, results from sensitivity analysis indicated that our conclusion was relatively stable.

Conclusions {#sec017}
===========

In conclusion, the present meta-analysis suggests that high homocysteine levels in women with PCOS are not related to degree of obesity, IR status, or androgen levels. Metformin treatment cannot decrease the homocysteine levels in PCOS patients.
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